| ￥3600 | |
| Z03967-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 87.4 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 110-130 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. | ||||||
| Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of VEGF R3/FLT4, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
VEGF R3/FLT4, His & Avi, Humanon Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
VEGF R3/FLT4, His&Avi, Human, His Tag immobilized on CM5 Chip can bind Human VEGF-C, His Tag with an affinity constant of 0.29 nM as determined in SPR assay (Biacore T200). »
| Target Background | Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors. |
| Synonyms | VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
